Nonsteroidal anti-inflammatory drugs (NSAIDs) induce apoptosis in cancer cells and this effect is involved in their antitumor activity. We recently demonstrated that NSAIDs upregulate GRP78, an endoplasmic reticulum (ER) chaperone, in gastric mucosal cells in primary culture. In the present study, induction of ER chaperones by NSAIDs and the effect of those chaperones on NSAID-induced apoptosis were examined in human gastric carcinoma cells. Celecoxib, an NSAID, upregulated ER chaperones (GRP78 and its cochaperones ERdj3 and ERdj4) but also C/EBP homologous transcription factor (CHOP), a transcription factor involved in apoptosis. Celecoxib also upregulated GRP78 in xenograft tumors, accompanying with the suppression of tumor growth in nude mice. Celecoxib caused phosphorylation of eukaryotic translation initiation factor 2 kinase (PERK) and eukaryotic initiation factor-2a (eIF2a) and production of activating transcription factor (ATF)4 mRNA. Suppression of ATF4 expression by small interfering RNA (siRNA) partially inhibited the celecoxib-dependent upregulation of GRP78. Celecoxib increased the intracellular Ca 2 þ concentration, while 1,2-bis(2-aminophenoxy) ethane-N,N,N 0 N 0 -tetraacetic acid, an intracellular Ca 2 þ chelator, inhibited the upregulation of GRP78 and ATF4. These results suggest that the Ca 2 þ -dependent activation of the PERK-eIF2a-ATF4 pathway is involved in the upregulation of ER chaperones by celecoxib. Overexpression of GRP78 partially suppressed the apoptosis and induction of CHOP in the presence of celecoxib and this suppression was stimulated by coexpression of either ERdj3 or ERdj4. On the other hand, suppression of GRP78 expression by siRNA drastically stimulated cellular apoptosis and production of CHOP in the presence of celecoxib. These results show that upregulation of ER chaperones by celecoxib protects cancer cells from celecoxib-induced apoptosis, thus may decrease the potential antitumor activity of celecoxib.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever (Smalley et al., 1995) . In addition, recent epidemiological studies clearly show that prolonged NSAID use is associated with a reduced risk of cancer, while preclinical and clinical studies have shown that some NSAIDs are effective in the treatment and prevention of cancer. This effect is particularly well documented in relation to colon and rectal cancer, with recent studies showing that NSAID use reduces the risk of stomach cancer (Farrow et al., 1998; Husain et al., 2002; Sorensen et al., 2003; Hu et al., 2004) . Of the various mechanisms proposed to explain the antitumor action of NSAIDs, such as cell growth suppression, inhibition of angiogenesis and inhibition of metastasis, NSAID-induced apoptosis in cancer cells is thought to play an important role (Gupta and Dubois, 2001; Kismet et al., 2004) .
The anti-inflammatory action of NSAIDs is mediated through the NSAID-induced inhibition of cyclooxygenase (COX). COX is an enzyme essential for the synthesis of prostaglandins (PGs), which have a strong propensity for inducing inflammation. PGs, such as PGE 2 , inhibit cellular apoptosis and the overexpression of COX-2 (a subtype of COX) has been reported to play a role in the development of various types of tumors (Eberhart et al., 1994; Piazza et al., 1995; Ristimaki et al., 1997; Hoshino et al., 2003) . Based on these reports, NSAID-induced apoptosis was believed to be based solely on its inhibitory effects on COX activity. However, several lines of evidence suggest that NSAID-induced apoptosis also involves COX-independent mechanisms. A derivative of the NSAID sulindac (sulindac sulfone), which has no COX-inhibitory activity, induced apoptosis in tumor cells and some NSAIDs have been shown to induce apoptosis in COX-null fibroblasts and in tumor cells in which COX expression was absent (Hanif et al., 1996; Elder et al., 1997; Zhang et al., 1999) . Therefore, it is important that the COX-independent mechanisms governing NSAID-induced apoptosis be identified.
NSAID-induced apoptosis in normal gastric mucosal cells seems to be involved in the production of gastric lesions by NSAIDs. We recently suggested that, in addition to COX inhibition by NSAIDs, the direct cytotoxicity of NSAIDs (induction of necrosis and apoptosis) contributes to the production of NSAIDinduced gastric lesions (Tomisato et al., 2001 (Tomisato et al., , 2004b . We examined the mechanism of NSAID-induced apoptosis in guinea pig gastric mucosal cells in primary culture and found that NSAIDs induce apoptosis by acting as endoplasmic reticulum (ER) stressors. Various NSAIDs induce C/EBP homologous transcription factor (CHOP), which is known to be important for the induction of apoptosis by ER stressors. Further to this, we showed, using CHOP-deficient mice or a dominant-negative form of CHOP, that this CHOP induction is essential for NSAID-induced apoptosis (Tsutsumi et al., 2004) .
In addition to inducing apoptosis, ER stressors cause upregulation of ER chaperones, which protect the ER against ER stressor activity by refolding unfolded proteins in the ER (Lee, 2001) . In fact, we reported that various NSAIDs induced the expression of glucoseregulated protein (GRP)-78, a representative ER chaperone, in gastric mucosal cells in primary culture (Tsutsumi et al., 2004) . However, it is not known if NSAIDs upregulate other ER chaperones such as ERdj3 and Erdj4, which act as cochaperones for GRP78 and activate the ATPase and refolding activity of GRP78 (Yu et al., 2000; Shen et al., 2002b) . Furthermore, it is also not known if NSAIDs induce ER chaperones in other types of cells, such as tumor cells. It was reported that overexpression of GRP78 makes cells resistant to apoptosis induced by anticancer drugs (topoisomerase inhibitors) and ER stressors (tunicamycin and Ca 2 þ ionophores) (Morris et al., 1997; Reddy et al., 2003) . Therefore, it is possible that the induction of GRP78 by NSAIDs contributes to the protection of cells from NSAID-induced apoptosis. In the present study, we have examined perturbations to ER chaperones by NSAIDs and the effect of such chaperones on NSAIDinduced apoptosis in human gastric carcinoma cells. Several NSAIDs upregulated not only GRP78 but also ERdj3 and ERdj4. We suggest that this upregulation is mediated by an increase in intracellular Ca 2 þ concentration. Furthermore, the contribution of ER chaperones to the protection of cells from celecoxib (a NSAID)-induced apoptosis was supported by experiments using overexpression plasmid and small interfering RNA (siRNA) for GRP78.
Results

NSAIDs upregulate ER chaperones
In a previous report, we showed that NSAIDs (such as celecoxib, indomethacin and diclofenac) upregulated GRP78 expression in guinea pig gastric mucosal cells in primary culture (Tsutsumi et al., 2004) . Here, we used immunoblotting techniques to examine the increase in GRP78 production in AGS cells caused by a number of different NSAIDs. As shown in Figure 1a , all NSAIDs tested clearly increased cellular levels of GRP78. The concentrations of celecoxib, indomethacin and diclofenac required for these increases in AGS cells were similar to those previously reported to have caused similar effects in guinea pig gastric mucosal cells (Tsutsumi et al., 2004) . COX exists as two subtypes, COX-1 and COX-2, for which celecoxib and nimesulide are COX-2 selective in their action. The results shown in Figure 1a suggest that NSAIDs increased cellular GRP78, irrespective of their COX-2 specificity. Furthermore, although celecoxib and nimesulide have similar IC 50 values for COX-inhibition (Riendeau et al., 1997; Ben-Chetrit et al., 2005) , higher concentrations of nimesulide than celecoxib were required for similar increases in GRP78 production, suggesting that NSAIDs increase GRP78 independently of COX inhibition. Of the NSAIDs tested (see results in Figure 1a ), we selected celecoxib for use in most of subsequent experiments because it increased GRP78 at the lowest concentration Figure 1 Upregulation of GRP78 by NSAIDs. AGS (a and c) or MKN-45 and Kato III (b) cells were incubated with indicated concentrations of stated NSAIDs for 12 h (celecoxib) or 24 h (NSAIDs other than celecoxib). Cells were pretreated with indicated concentrations of PGE 2 for 2 h before the celecoxib treatment (c). Whole cell extracts (5 mg protein) were analysed by immunoblotting with an antibody against GRP78 or actin. Band intensity of GRP78 was determined by densitometric scanning, gelloading levels compensated against the band intensity of actin, and expressed relative to the control sample (i.e. without NSAIDs). and its effectiveness in cancer therapy has been well established .
We also examined the upregulation of GRP78 by celecoxib in other cell types. The MKN-45 and Kato III cell lines are derived from gastric cancer cells . As shown in Figure 1b , celecoxib increased GRP78 mRNA in both of these cell lines at concentrations similar to those used for the AGS cells. It has been reported that both COX-1 and COX-2 mRNA are expressed in AGS and MKN-45 cells, whereas COX-1 but not COX-2 mRNA expression is detectable in KATO-III cells (Kawai et al., 1998; Fan et al., 2001; Lim et al., 2001) . We confirmed these phenotypes by RT-PCR, that is, COX-1 mRNA expression was confirmed in each of the cell lines tested, whereas COX-2 mRNA was detected only in AGS and MKN-45 cells (data not shown). Thus, the results in Figure 1 show that the COX-2-selective NSAID, celecoxib, upregulated GRP78 mRNA not only in COX-2-expressing cells but also in cells lacking COX-2 expression, again suggesting that GRP78 upregulation can be induced by NSAIDs independently of COX inhibition. For further confirmation of this independence, we examined the effect of PGE 2 on the GRP78 upregulation by celecoxib. As shown in Figure 1c , PGE 2 did not affect the expression of GRP78 in both presence and absence of celecoxib, suggesting that the GRP78 upregulation by celecoxib cannot be explained by decrease in PGE 2 by COX inhibition.
GRP78 belongs to the HSP70 family of proteins for which cochaperones are also known (Lee, 2001) . For example, HSP40 binds to HSP70 and stimulates its ATPase and refolding activities (Landry, 2003) . Various cochaperones have been suggested for GRP78, among which ERdj3 and ERdj4 have been shown to bind to GRP78 and activate its ATPase activity (Yu et al., 2000; Shen et al., 2002b) . We found, using real-time RT-PCR analysis, that not only GRP78 but also ERdj3 and ERdj4 mRNAs were upregulated by celecoxib (see Figure 2) . The concentrations of celecoxib required for the increase of both ERdj3 and ERdj4 mRNAs were similar to that required for the increase of GRP78 mRNA (Figure 2a) . Moreover, the curve describing the time course for the upregulation by celecoxib of GRP78 mRNA was indistinguishable from those for ERdj3 and ERdj4 mRNAs (Figure 2b) , showing that celecoxib simultaneously upregulates GRP78, ERdj3 and ERdj4.
We also examined the effect of treatment with celecoxib on GRP78 expression in xenograft tumors in nude mice. Tumors were developed in nude mice by inoculation (s.c.) of MKN-45 cells and were treated with celecoxib by its oral administration. Xenograft tumor growth was clearly inhibited by the oral administration of celecoxib (Figure 3a ), being consistent with results in a previous report (Williams et al., 2000; Leahy et al., 2002; Zweifel et al., 2002; Kulp et al., 2004) . As shown in Figure 3b and c, the amount of GRP78 in tumors was increased by this celecoxib treatment. Results showed that celecoxib upregulates GRP78 also in tumors in vivo, accompanying with the suppression of tumor growth by this drug.
Mechanism for upregulation of ER chaperones by celecoxib Eukaryotic translation initiation factor 2 kinase (PERK) is an ER transmembrane protein that plays an important role in ER chaperone induction by ER stressors. Previous studies revealed that ER stressors activate PERK by its phosphorylation, the PERK then activates eukaryotic initiation factor-2a (eIF2a) by its phosphorylation, the eIF2a induces activating transcription factor (ATF)4 expression, and finally, ATF4 binds to the promoter of the GRP78 gene, resulting in the increased production of GRP78 Luo et al., 2003) . We used DNA microarray techniques to search for genes whose expression is stimulated by NSAIDs in AGS cells (Mima et al., 2005) . ATF4 was identified as one such gene, suggesting that its upregulation is involved in the induction of ER chaperones by NSAIDs. As shown in Figure 4a , both PERK and eIF2a were phosphorylated in the presence of celecoxib. The PERK phosphorylation was transient; it decreased after 3 h and we have no . Both time-course and dose-response curves for upregulation of ATF4 mRNA were similar to those observed for the increase of GRP78 mRNA by celecoxib (Figures 2 and 4) . Interestingly, phosphorylation of PERK was detected within 1.5 h of the addition of celecoxib, maximal eIF2a was reached 6 h after addition and peak ATF4 mRNA and protein was observed 12 h after addition (Figure 4 ), suggesting that the sequential activation of PERK, eIF2a and ATF4 is involved in the upregulation of GRP78. To test this possibility, we examined the effect of siRNA for ATF4 on the celecoxib-dependent upregulation of GRP78. Transfection of siRNA for ATF4 clearly inhibited the expression of ATF4 mRNA, both in the presence and absence of celecoxib ( Figure 5a ). As shown in Figure 5b , transfection of siRNA for ATF4 partially suppressed the increase of GRP78 mRNA production caused by celecoxib, suggesting that ATF4 is involved in this celecoxib-dependent GRP78 upregulation. In order to estimate the specificity of this siRNA, we examined its effect on the expression of mRNA of other CREB protein family member (ATF2 and ATF3). As shown in Figure 5c , transfection of siRNA for ATF4 did not affect the celecoxib-dependent induction of ATF2 mRNA so clearly as that of ATF4, suggesting that this siRNA specifically inhibited the expression of ATF4 mRNA. On the other hand, transfection of this siRNA inhibited the induction of ATF3 mRNA by celecoxib ( Figure 5d ). This may be due to the dependence of ATF3 expression on ATF4; the upregulation of ATF3 by thapsigargin was significantly suppressed in ATF4 knockout cells (Jiang et al., 2004) . . Then indicated dose of celecoxib was administered single daily orally for the duration of the study. Tumors were measured weekly and their volumes calculated (a). After 4 days from the start of celecoxib administration, cell lyzates prepared from tumors were analysed by immunoblotting with an antibody against GRP78 or actin (b). Band intensity of GRP78 was determined by densitometric scanning, compensated against the band intensity of actin, and expressed relative to the control sample (i.e. without celecoxib) (c). Values given are mean7s.d. (n ¼ 6 for (a) and n ¼ 3 for (b and c)). ***Po0.001; **Po0.01; *Po0.05. 
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Some NSAIDs have been reported to increase intracellular Ca 2 þ concentrations (Johnson et al., 2002; Tomisato et al., 2004a) . We recently found that all of the NSAIDs tested can cause membrane permeabilization, resulting in an increase in intracellular Ca 2 þ levels. This activity correlates well with the NSAID-induced apoptosis (Tomisato et al., 2004a) . On this basis, we have tested whether the increase in intracellular Ca 2 þ by celecoxib is responsible for the induction of ER chaperones. First, we confirmed the presence of an increase in intracellular Ca 2 þ concentration in the presence of celecoxib under the same conditions as those used for the upregulation of GRP78 in AGS cells. As shown in Figure 6a , celecoxib increased intracellular Ca 2 þ concentration in a dose-dependent manner, similar to that observed for the increase in GRP78 mRNA ( Figure 2a) . Furthermore, 1,2-bis(2-aminophenoxy)-ethane-N,N,N 0 N 0 -tetraacetic acid (BAPTA-AM), an intracellular Ca 2 þ chelator, inhibited the celecoxibdependent upregulation of GRP78, GRP78 mRNA and ATF4 mRNA (Figure 6b-d) , but had no effect when celecoxib was not present. At the concentrations used, BAPTA-AM did not affect the cell viability (data concentration was monitored by a fluo-3/AM assay system. Indicated concentrations of celecoxib were added to fluo-3/AMloaded cells and the time-course of fluo-3 fluorescence change monitored. The maximum value for the increase in the intracellular
. AGS cells were preincubated with or without 2 mM BAPTA-AM for 1 h and further incubated with or without 80 mM celecoxib (b-d), 800 mM nimesulide (e), 800 mM diclofenac (f) or 400 mM indomethacin (g) in the presence or absence of 2 mM BAPTA-AM for 6 h (celecoxib) or 12 h (other NSAIDs). The levels of GRP78 protein (b, e-g), GRP78mRNA (c) and ATF4 mRNA (d) were estimated by immunoblotting or realtime RT-PCR experiments as described in the legends of Figures 1 and 2. AGS cells were incubated with 100 mM celecoxib or 2 mM thapsigargin for indicated periods (h). Whole cell extracts (25 mg protein for ATF6 and 10 mg protein for actin) (upper panel in (h)) or nuclear extracts (20 mg protein for p50 ATF6 and 5 mg protein for lamin B) (lower panel in (h)) were analysed by immunoblotting with an antibody against ATF6, actin or lamin B as described in the legends of Figure 1 . As for p50 ATF6 band, intensity of each band was expressed relative to the positive control sample (i.e. cells treated with thapsigargin for 1.5 h). Values shown are mean7s.d. (n ¼ 3). ***Po0.001; **Po0.01; *Po0.05.
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We also examined the effect of BAPTA-AM on the upregulation of GRP78 induced by other NSAIDs. As is the case of celecoxib, BAPTA-AM inhibited the upregulation of GRP78 by nimesulide or diclofenac (Figure 6e and f) . On the other hand, BAPTA-AM did not affect the upregulation of GRP78 by indomethacin (Figure 6g) .
ATF6 is another type of ER transmembrane protein that also plays an important role in ER chaperone induction by ER stressors. We previously suggested that ATF6 is activated in the presence of NSAIDs in gastric mucosal cells in primary culture (Tsutsumi et al., 2004) , and it was recently reported that ATF6 is activated by nitric oxide through an increase in the intracellular Ca 2 þ level (Xu et al., 2004) . Therefore, we examined the effect of celecoxib on the activation of ATF6. In the presence of ER stressors, such as thapsigargin, p90 ATF6 (the inactive form of ATF6 for ER stress response) is cleaved into p50 ATF6, which translocates to the nucleus where it specifically activates transcription of genes related to ER stress response (Yoshida et al., 2000) . As shown in Figure 6h , as well as thapsigargin, treatment of cells with celecoxib caused appearance of p50 ATF6 and disappearance of p90 ATF6, suggesting that celecoxib activated ATF6. This activation was transient; both appearance of p50 ATF6 and disappearance of p90 ATF6 was apparent 3 h but not observed 12 h after the addition of celecoxib.
Effect of ER chaperones on celecoxib-induced apoptosis
It is well known that celecoxib induces apoptosis in various types of tumor cells . As shown in Figure 7a and b, celecoxib induced apoptosis in AGS cells in both a dose-and timedependent manner. Real-time RT-PCR analysis showed that celecoxib induced CHOP mRNA production, with the dose-response and time-course curves for this response (Figure 7c and d) being similar to those seen for the induction of apoptosis (Figure 7a and b). This finding suggests that the induction of CHOP expression is responsible for the celecoxibinduced apoptosis, as reported previously (Tsutsumi et al., 2004) .
The dose-response and time-course curves for the upregulation of GRP78 by celecoxib ( Figure 2) were also similar to those for the induction of apoptosis (Figure 7a and b) , showing that GRP78 upregulation and apoptosis occur simultaneously. Previous reports showed that overexpression of GRP78 in cells suppresses apoptosis induced by topoisomerase inhibitors and ER stressors (Morris et al., 1997; Reddy et al., 2003) . Therefore, it is possible that celecoxib-induced GRP78 protects cells from celecoxib-induced apoptosis. In order to test this possibility, we examined the effect of overexpression of GRP78 on celecoxib-induced apoptosis. Transfection of pcDNA3.1 containing the GRP78 gene caused both an increase in the level of GRP78 in cells and partial suppression of celecoxib-induced apoptosis in a manner that depended on the dose of transfected DNA (Figure 8a and b) . Real-time RT-PCR analysis revealed that the transfection increased GRP78 mRNA both in the presence and absence of celecoxib (Figure 8c) . Furthermore, the transfection partially suppressed the celecoxib-dependent induction of CHOP mRNA (Figure 8d ). We confirmed that overexpression of GRP78 did not affect the spontaneous apoptosis (apoptosis in the absence of celecoxib) (Figure 9d ). These results suggest that the celecoxib-induced increase in GRP78 expression protects cells from celecoxibinduced apoptosis by repressing the expression of CHOP mRNA. Overexpression of GRP78 did not diminish the celecoxib-dependent GRP78 upregulation (Figure 8c) , which is inconsistent with previous results showing that overexpression of GRP78 diminished tunicamycin-dependent GRP78 production (Morris et al., 1997) . This discrepancy may be explained by differences in stressors or in the extent of overexpression (the extent of overexpression of GRP78 in the paper by Morris et al. was much higher than that found here).
It was recently reported that overexpression of ERdj4 in cells inhibits apoptosis induced by tunicamycin (Kurisu et al., 2003) . We here examined the effect of overexpression of ERdj4, ERdj3, or their coexpression with GRP78 on celecoxib-induced apoptosis. As shown in Figure 9a , transfection of plasmid resulting in overexpression of ERdj3 partially suppressed the cele- coxib-induced apoptosis in a manner that was dependent on the amount of transfected DNA. Furthermore, the cotransfection of plasmids for the overexpression of both GRP78 and ERdj3 caused a more clear-cut suppression of celecoxib-induced apoptosis than did transfection of each plasmid alone (Figure 9a ). Similar results were obtained for ERdj4 (Figure 9b ). We confirmed that overexpression of both GRP78 and ERdj3 or ERdj4 did not affect the spontaneous apoptosis (apoptosis in the absence of celecoxib) (Figure 9d ). These results suggest that the ERdj4 and ERdj3 cochaperones stimulate the antiapoptotic effect of GRP78 against the actions of celecoxib.
The J domain of HSP40 family proteins is responsible for their interaction with HSP70 family proteins (Landry, 2003) . It was shown that J domain-deleted ERdj4 (ERdj4DJ) could not interact with GRP78 and activate the ATPase activity of GRP78 (Shen et al., 2002b) . As shown in Figure 9c , in contrast to the results obtained with wild-type ERdj4, transfection of plasmid for the overexpression of ERdj4DJ caused neither the suppression of celecoxib-induced apoptosis nor stimulation of an antiapoptotic effect of GRP78 against celecoxib. These findings suggest that the antiapoptotic effects of ERdj4 are achieved via its interaction with GRP78.
The siRNA technique was used to further confirm that celecoxib-induced GRP78 protects cells from celecoxib-induced apoptosis. Transfection of siRNA for GRP78 decreased the expression of GRP78 protein ( Figure 10a ) and GRP78 mRNA (Figure 10b) , both in the presence and absence of celecoxib, and also stimulated celecoxib-induced apoptosis and CHOP mRNA expression (Figure 10e and f) . In order to estimate the specificity of siRNA for GRP78, we examined its effect on the expression of mRNA of other ER chaperons (ERdj3 and ERdj4). As shown in Figure  10c and d, transfection of siRNA for GRP78 significantly increased the ERdj3 or ERdj4 mRNA in both presence and absence of celecoxib, suggesting that this siRNA specifically inhibit the expression of GRP78. The stimulation of the ERdj3 or ERdj4 mRNA expression by this siRNA may be due to that GRP78 negatively regulated the ER stress response; GRP78 binds to PERK and protein-kinase and site-specific endoribonuclease (IRE1) and inhibits their activity for inducing ER stress response (Bertolotti et al., 2000) . These results strongly suggest that celecoxib-induced GRP78 protects ER chaperones and celecoxib-induced apoptosis S Tsutsumi et al cells from apoptosis in the presence of celecoxib. Furthermore, the stimulation of apoptosis and CHOP mRNA expression by transfection of siRNA for GRP78 in the absence of celecoxib suggests that constitutively expressed GRP78 under nonstress conditions contributes to cell survival. We also tried to examine the effect of siRNA for GRP78 on apoptosis induced by chemotherapy drug without ability to induce ER stress response. As shown in Figure 10h , staurosporine, a chemotherapy drug, did not upregulate GRP78 at concentrations that are enough to induce apoptosis ( Figure 10g ). As shown in Figure 10g , transfection of siRNA for GRP78 slightly stimulated apoptosis induced by staurosporine. This slight stimulation can be explained by its effect on the spontaneous apoptosis (apoptosis in the absence of drugs). In other words, the extent of the stimulation was not so drastic as is the case of celecoxib (Figure 10e) . Suppression of GRP78 through siRNA for GRP78 sensitized human breast cancer cells to etoposidemediated cell death (Dong et al., 2005) . These results suggested that the stimulatory effect of siRNA for GRP78 on apoptosis is apparent for apoptosis induced by chemotherapy drugs that induce ER stress response.
Discussion
In this study, we have shown that several NSAIDs upregulate ER chaperones not only in various types of cultured human gastric cancer cells but also in xenograft tumors in nude mice. We reported previously that a number of different NSAIDs upregulate GRP78 in guinea pig gastric mucosal cells in primary culture (Tsutsumi et al., 2004) . Furthermore, we recently found that NSAIDs upregulate ER chaperones in HEK293 cells (human embryonic kidney cells) (Hoshino T et al., unpublished results) . Therefore, it seems that NSAIDs upregulate ER chaperones as a part of their general mechanism of action. Concentrations of NSAIDs required for induction of GRP78 in vitro (60-100 mM) are relatively higher than clinical available concentrations of celecoxib (1-10 mM) (Lopez-Parra et al., 2005; Patel et al., 2005) . It was reported that oral administration of celecoxib (100-200 mg/kg/day, similar conditions to our experiments in Figure 3 ) caused serum concentrations of 8.6-11.3 mM (Kulp et al., 2004) . Therefore, under in vivo conditions, lower concentrations of celecoxib may be able to induce GRP78 than under in vitro conditions. This induction is likely to be mediated by COX-independent mechanisms, given that NSAIDs Figure 10 Effect of GRP78 siRNA on celecoxib-induced apoptosis. AGS cells were transfected with 5 mg of siRNA for GRP78 (siGRP78) or nonsilencing (ns) siRNA. After 48 h, cells were incubated with or without 80 mM celecoxib (a-d and f), indicated concentrations of celecoxib (e) or indicated concentrations of staurosporine (g and h) for 6 h. The levels of GRP78 protein (a and h), GRP78 mRNA (b), ERdj3 mRNA (c), ERdj4 mRNA (d) and CHOP mRNA (f) were estimated by immunoblotting or real-time RT-PCR experiments as described in the legends of Figures 1 and  2 . Apoptotic cell numbers were determined by FACS as described in the legend of (Figure 7e and g ). Values shown are mean7s.d. (n ¼ 3). ***Po0.001; **Po0.01; *Po0.05. increased GRP78 production irrespective of their COX-2 specificity and that COX-2-selective NSAIDs (celecoxib) upregulated GRP78 in cells that did not express COX-2. Furthermore, although indomethacin at a concentration of less than 1 mM inhibited both COX-1 and COX-2 (Kawai et al., 1998) , the upregulation of GRP78 required higher concentrations. The IC 50 value of celecoxib for COX-2 inhibition is about 40 nM (Schroeder et al., 2004; Ben-Chetrit et al., 2005) , which is much lower than the concentration required for the upregulation of GRP78 (about 60 mM).
The results in this study suggest that the upregulation of ER chaperones by celecoxib involves the PERKeIF2a-ATF4 pathway. Other recent papers also suggest the importance of this pathway in the upregulation of ER chaperones by other ER stressors (Luo et al., 2003; Roybal et al., 2004) . However, siRNA for ATF4 did not completely inhibit the celecoxib-dependent GRP78 upregulation, suggesting that pathways other than the PERK-eIF2a-ATF4 pathway are involved in this mechanism. In addition to PERK, two other ER transmembrane proteins (ATF6 and IRE1) are involved in the ER stress response. Activated ATF6 translocates to the nucleus where it specifically binds to the promoter of ER chaperone genes, while IRE1 splices X boxbinding protein XBP-1 mRNA, to convert it into a potent activator for the transcription of ER chaperone genes. (Yoshida et al., 2000; Kaufman, 2002; Ron, 2002) We suggest that both ATF6 and IRE1 are activated in the presence of NSAIDs in gastric mucosal cells in primary culture (Tsutsumi et al., 2004) , and we here showed that ATF6 is activated by celecoxib even in AGS cells.
It is well known that an increase in the intracellular Ca 2 þ concentration induces ER chaperone; Ca 2 þ ionophores, for example, induce ER chaperone (Drummond et al., 1987; Wooden et al., 1991) . We suggested that an increase in intracellular Ca 2 þ concentration is involved in the celecoxib-dependent upregulation of ER chaperones based on the following observations: celecoxib increased the intracellular Ca 2 þ concentration and expression of ER chaperones simultaneously; and the intracellular Ca 2 þ chelator, BAPTA-AM, inhibited the celecoxib-dependent upregulation of ER chaperones. BAPTA-AM also inhibited the GRP78 upregulation caused by nimesulide or diclofenac but not by indomethacin. We recently showed that all of NSAIDs tested (including nimesulide and diclofenac) increased the intracellular Ca 2 þ level (Tomisato et al., 2004a; Tanaka et al., 2005) . Since indomethacin absorbed fluo-3 fluorescence (530 nm), we could not measure the intracellular Ca 2 þ level in the presence of indomethacin by the assay system using fluo-3 (Tanaka et al., 2005) . Therefore, it seems that not only celecoxib but also most of NSAIDs induce GRP78 through increasing the intracellular Ca 2 þ level and that indomethacin induces GRP78 through different unknown mechanism. As for the mechanism for the increase in the intracellular Ca 2 þ level, both inhibition of sarcoplasmic/ER Ca 2 þ ATPase (sarco endoplasmic reticulum Ca 2 þ ATPase; an ERlocated Ca 2 þ pump that is responsible for accumulation of Ca 2 þ in the ER) and stimulation of the influx of extracellular Ca 2 þ have been proposed (Johnson et al., 2002; Wang et al., 2004) . We recently found that all of the NSAIDs tested permeabilize cellular membranes and this capacity of NSAIDs is closely related to their activity for increasing intracellular Ca 2 þ concentration, suggesting that NSAIDs stimulate the influx of extracellular Ca 2 þ by permeabilizing cytoplasmic membranes (Tomisato et al., 2004a; Tanaka et al., 2005) . Since the suppression of celecoxib-dependent GRP78 upregulation by BAPTA-AM was partial, a further mechanism other than an increase in the intracellular Ca 2 þ level may be involved in the upregulation of GRP78. Accumulation of unfolded proteins in the ER by inhibition of the proteasome system may be involved in this upregulation; it was suggested that NSAIDs inhibit the proteasome system and that specific inhibitors of the proteasome system, such as MG132, induce the ER stress response (Bush et al., 1997; Huang et al., 2002) .
Overproduction of GRP78 in cells was reported to make them resistant to apoptosis induced by topoisomerase inhibitors, tunicamycin or Ca 2 þ ionophores (Morris et al., 1997; Reddy et al., 2003) . We showed here that this phenomenon can be applied to celecoxibinduced apoptosis and that the antiapoptotic effect of GRP78 is stimulated by coexpression of its cochaperones, ERdj3 and ERdj4. This effect of ERdj4 depends on its J domain, as was the case for stimulation of the antiapoptotic effect of HSP70 by HSP40 (Gotoh et al., 2001) . Since the J domain of ERdj4 is essential for its interaction with GRP78 and its activation of GRP78 ATPase activity, the stimulation by ERdj4 (and also ERdj3 presumably) of the antiapoptotic activity of GRP78 should be mediated by this physical and functional interaction between them.
We previously used CHOP-deficient mice or a dominant-negative form of CHOP to show that CHOP, a transcription factor with apoptosis-inducing activity, is essential for NSAID-induced apoptosis (Tsutsumi et al., 2004) . Since induction of CHOP by celecoxib is partially suppressed by the overproduction of GRP78, it is reasonable to speculate that this suppression is involved in the antiapoptotic effect of GRP78. It was suggested that GRP78 binds to PERK (and also IRE1 and ATF6) and inactivates PERK's ER stress response inducing capabilities under nonstress conditions; when ER stressors accumulate unfolded proteins in the ER, PERK (and also IRE1 and ATF6) is activated to induce the ER stress response by releasing GRP78 from PERK, as a result of the binding of unfolded proteins to GRP78 (Bertolotti et al., 2000; Shen et al., 2002a) . Induction of GRP78 by proteasome inhibitors has been reported (Hong et al., 2004) . It was reported that overexpression of GRP78 inhibited the phosphorylation of PERK in the presence of an ER stressor (thapsigargin) (Bertolotti et al., 2000) . Therefore, we consider that by this mechanism, overproduced GRP78 suppressed the celecoxib-dependent CHOP induction and resulting apoptosis. It was also suggested that GRP78 inhibits topoisomerase inhibitor-induced apoptosis by inhibiting caspase-7 (Reddy et al., 2003) , which may also be involved in the antiapoptotic effect of GRP78 against NSAIDs.
Resistance to chemotherapy is one of the major obstacles of cancer therapy. Owing to poor vascularization, solid tumors usually exist under conditions of glucose starvation and hypoxia, which causes induction of the ER stress response. In fact, overproduction of ER chaperones was reported in various types of tumors and artificial overproduction of ER chaperones stimulated tumor progression (Jamora et al., 1996; Koomagi et al., 1999; Fernandez et al., 2000; Song et al., 2001; Huo et al., 2004) . Therefore, the finding in this study that overproduction of GRP78 makes cancer cells resistant to celecoxib is very important in considering the use of celecoxib in chemotherapy; it seems that not only constitutively overproduced ER chaperones in tumors but also ER chaperones induced by NSAIDs can make them resistant to chemotherapy by NSAIDs. In fact, we showed that orally administered celecoxib caused both inhibition of xenograft tumor growth and induction of GRP78 simultaneously in nude mice. We consider that GRP78 upregulation by celecoxib decreases the activity of this drug for the suppression of tumor growth and thus propose that an inhibitor of ER chaperones may be of clinical benefit by making tumor cells more responsive to NSAIDs.
Materials and methods
Chemicals, plasmids and animals RPMI 1640 medium was obtained from Nissui Pharmaceutical Co. Fetal bovine serum (FBS) was obtained from Gibco Co. Pluronic F127, fluo-3/AM and BAPTA-AM were from Dojindo Co. Thapsigargin, staurosporine, diclofenac, RNaseA and propidium iodide (PI) were obtained from Sigma Co. PGE 2 and indomethacin were obtained from Wako Co. Celecoxib was from LKT Laboratories Inc. Nimesulide was from Cayman Chemical Co. Antibodies against GRP78, ATF6, lamin, ATF4 and actin were purchased from Santa Cruz Biotechnology Inc., and those against phosphorylated PERK and phosphorylated eIF2a were from Cell Signaling Technology Inc. The RNeasy kit, siRNAs and RNAiFect transfection reagent were from Qiagen. A first-strand cDNA synthesis kit was purchased from Amersham. Lipofectamine (TM2000) and pcDNA3.1 plasmid were obtained from Invitrogen. SYBR GREEN PCR Master Mix was from ABI. A plasmid of pEGFP-N1 was obtained from Clontech. Plasmids of pcDNA3.1/GRP78 and pCR3.1/ERdj3 were gifts from Drs Austin R and Haslam D, respectively. Plasmids of pcDNA3.1/ERdj4 and pcDNA3.1/ERdj4DJ were a gift from Dr K Imaizumi. Female ICR nude mice (5 weeks of age) were obtained from the Kyudoh Co. The experiments and procedures described here were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of Health and were approved by the Animal Care Committee of Kumamoto University.
Cell culture and overexpression of ER chaperones Cells were cultured in RPMI1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified atmosphere of 95% air with 5% CO 2 at 371C. NSAIDs were dissolved in DMSO and control experiments (without NSAIDs) were performed in the presence of the same concentrations of DMSO. Cells were exposed to NSAIDs by changing the medium. Unless otherwise noted, cells (0.8 Â 10 4 cells per well in 24-well plates, 4 Â 10 4 cells per well in six-well plates, 6 Â 10 5 cells in 100-mm plates) were cultured for 24 h and used in experiments. For transient expression of each gene, cells were seeded 24 h before transfection in six-well plates at a density of 5 Â 10 5 /well. The transfection with pcDNA3.1 containing each gene was carried out using Lipofectamine (TM2000) according to the manufacturer's instructions. Cells were used for experiments after a 48 h recovery period. Transfection efficiency was determined in parallel plates by transfection of the pEGFP-N1 control vector. Transfection efficiency was more than 80% in all experiments.
Analysis of apoptosis by fluorescence-activated cell sorting (FACS) Apoptosis was monitored by FACS analysis as described previously (Alves da Costa et al., 2002) . Briefly, cells were cultured in 100-mm plates and collected by centrifugation. Pellets were fixed with 70% ethanol for 4 h at À201C and centrifuged again. Pellets were resuspended in phosphatecitrate buffer (0.2 M Na 2 HPO 4 and 4 mM citric acid) and incubated for 20 min at RT. After centrifugation, the pellets were resuspended in DNA staining solution (50 mg/ml PI and 10 mg/ml RNaseA) and incubated for 20 min at RT. Samples were scanned with a FACSCalibur (Becton Dickinson) cell sorter under conditions to measure only specific PI-mediated fluorescence. The signal threshold was determined based on the fluorescence of nontransfected cells. Apoptotic cells appeared as a hypodiploid peak due to nuclear fragmentation and loss of DNA.
Real-time RT-PCR analysis
Total RNA was extracted from cells using an RNeasy kit according to the manufacturer's protocols. Samples (10 mg RNA) were reverse-transcribed using a first-strand cDNA synthesis kit according to the manufacturer's instructions. Synthesized cDNA was applied to real-time RT-PCR (ABI PRISM 7700) using SYBR GREEN PCR Master Mix and analysed with ABI PRISM 7700 Sequence Detection Software according to the manufacturer's instructions. Real-time cycle conditions were 2 min at 501C, followed by 10 min at 901C and then for 45 cycles at 951C for 30 s and 631C for 60 s. Specificity was confirmed by electrophoretic analysis of the reaction products and by inclusion of template-or reverse transcriptase-free controls. To normalize the amount of total RNA present in each reaction, the actin gene was used as an internal standard.
Primers were designed using the Primer3 website (http:// frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primers are listed as follows: gene name: forward primer, reverse primer. ATF4: 5 0 -tcaaacctcatgggttctcc-3 0 , 5 0 -gtgtcatccaacgtggtcag-3 0 ; AT F2: 5-ctccagctcacacaactcca-3 0 , 5 0 -gtttcagctgtgccacttca-3 0 ; ATF3: 5'-atgatgcttcaacacccaggc-3 0 , 5'-ttagctctgcaatgttccttcc-3 0 ; CHOP:
Immunoblotting analysis Whole-cell extracts were prepared as described previously (Tsutsumi et al., 2002) . The protein concentration of samples was determined by the Bradford method. Samples were applied to 8% (for PERK and GRP78) or 10% (for eIF2a and actin) polyacrylamide SDS gels, subjected to electrophoresis, and proteins then immunoblotted with respective antibodies.
Xenograft tumor growth
Effect of celecoxib on xenograft tumor growth was examined as described previously (Kulp et al., 2004) . Each nude mouse was inoculated s.c. in the right hind footpad with 2 Â 10 6 cells of MKN-45 suspended in 0.1 ml of serum-free medium. When tumors reached a mean volume of 116734 mm 3 , mice started to receive single daily oral administration of celecoxib (100 or 200 mg/kg (body weight)) in 1% methylcellulose and this administration was continued for the duration of the study. Control mice received vehicle (1% methylcellulose only). Tumors were measured weekly using calipers and their volumes calculated using the following standard formula: width 2 Â length Â 0.5. Body weights were measured daily. For examination of GRP78 expression in tumors, tumor xenografts (dissected into o1-mm pieces) were solubilized with RIPA buffer (50 mM Tris-HCl (pH7.2), 150 mM NaCl, 1% NP-40, 1% Sodium deoxycholate and 0.05% SDS) and subjected to immunoblotting analysis.
Measurement of intracellular Ca
2 þ levels The intracellular Ca 2 þ levels were monitored according to manufacture's protocols (Kao et al., 1989) . Cells were washed with assay buffer (115 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgCl 2 , 20 mM HEPES and 13.8 mM glucose). Cells were then incubated with 4 mM fluo-3/AM in the assay buffer also containing 0.1% BSA, 0.04% Pluronic F127 and 2 mM probenecid for 40 min at 371C. After washing twice with the assay buffer, cells were suspended in assay buffer also containing 2 mM probenecid. Fluo-3 fluorescence of cells in a water-jacketed cuvette (1.6 Â 10 6 cells/cuvette) was measured with a HITACHI F-4500 spectrofluorophotometer by recording excitation signals at 490 nm and the emission signal at 530 nm at 1-second intervals. Maximum and minimum fluorescence values (F max and F min ) were obtained by adding 10 mM ionomycin and 10 mM ionomycin plus 5 mM EGTA (in Ca 2 þ -free medium), respectively. 
SiRNA targeting of genes
We used siRNA of 5 0 -ggagcgcauugauacuagadTdT-3 0 and 5 0 -ucuaguaucaaugcgcuccdTdT-3 0 or 5 0 -gccuaggucucuuagaugadTdT-3 0 and 5 0 -ucaucuaagagaccuaggcdTdT-3 0 as annealed oligonucleotides for repressing GRP78 or ATF4 expression, respectively. AGS cells were transfected with siRNA using RNAiFect transfection reagent according to the manufacturer's instructions. Nonsilencing siRNA (5 0 -uucuccgaacgugu cacgudTdT-3 0 and 5 0 -acgugacacguucggagaadTdT-3 0 ) was used as a negative control.
Statistical analysis
All values are expressed as the mean7standard deviation (s.d.). One-way analysis of variance (ANOVA) followed by Scheffe's multiple comparison test was used for evaluation of differences between groups. The Student's t-test for unpaired results was used for the evaluation of differences between two groups. Differences were considered to be significant for values of Po0.05.
Abbreviations
ATF, activating transcription factor; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N 0 N 0 -tetraacetic acid; CHOP, C/ EBP homologous transcription factor; COX, cyclooxygenase; eIF2a, eukaryotic initiation factor-2a; ER, endoplasmic reticulum; FACS, fluorescence-activated cell sorting; FBS, fetal bovine serum; IRE1, protein-kinase and site-specific endoribonuclease; NSAIDs, non-steroidal anti-inflammatory drugs; PERK, eukaryotic translation initiation factor 2 kinase; PG, prostaglandin; PI, propidium iodide; SERCA, sarco endoplasmic reticulum Ca 2 þ ATPase; siRNA, small interfering RNA; XBP-1, X box binding protein.
